Equities analysts forecast that Inovio Pharmaceuticals, Inc. (NASDAQ:INO) will post ($0.29) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Inovio Pharmaceuticals’ earnings, with estimates ranging from ($0.33) to ($0.24). Inovio Pharmaceuticals posted earnings of ($0.36) per share during the same quarter last year, which suggests a positive year over year growth rate of 19.4%. The business is scheduled to issue its next quarterly earnings report on Wednesday, March 21st.
On average, analysts expect that Inovio Pharmaceuticals will report full year earnings of ($1.12) per share for the current fiscal year, with EPS estimates ranging from ($1.18) to ($1.03). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.28) per share, with EPS estimates ranging from ($1.47) to ($1.04). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that cover Inovio Pharmaceuticals.
Inovio Pharmaceuticals (NASDAQ:INO) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.15). The company had revenue of $2.60 million for the quarter, compared to the consensus estimate of $10.27 million. Inovio Pharmaceuticals had a negative return on equity of 72.19% and a negative net margin of 221.55%. The firm’s revenue for the quarter was down 79.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.28) earnings per share.
INO has been the subject of several research reports. HC Wainwright set a $13.00 price target on Inovio Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 9th. Maxim Group set a $12.00 target price on shares of Inovio Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 9th. Finally, Citigroup Inc. initiated coverage on shares of Inovio Pharmaceuticals in a research report on Wednesday, September 6th. They set a “buy” rating and a $10.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $19.16.
Several institutional investors and hedge funds have recently added to or reduced their stakes in INO. Virginia Retirement Systems ET AL purchased a new position in Inovio Pharmaceuticals in the third quarter worth $101,000. BlueCrest Capital Management Ltd purchased a new position in Inovio Pharmaceuticals in the second quarter worth $107,000. Neuberger Berman Group LLC purchased a new position in Inovio Pharmaceuticals in the third quarter worth $115,000. Engineers Gate Manager LP purchased a new position in Inovio Pharmaceuticals in the third quarter worth $117,000. Finally, Emerald Advisers Inc. PA grew its position in Inovio Pharmaceuticals by 84.0% in the third quarter. Emerald Advisers Inc. PA now owns 20,323 shares of the biopharmaceutical company’s stock worth $129,000 after acquiring an additional 9,280 shares in the last quarter. Hedge funds and other institutional investors own 26.44% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Analysts Anticipate Inovio Pharmaceuticals, Inc. (INO) to Post -$0.29 Earnings Per Share” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://stocknewstimes.com/2017/11/20/analysts-anticipate-inovio-pharmaceuticals-inc-ino-to-post-0-29-earnings-per-share.html.
Shares of Inovio Pharmaceuticals (INO) traded up $0.08 during trading on Monday, reaching $4.72. The company’s stock had a trading volume of 923,300 shares, compared to its average volume of 1,279,729. Inovio Pharmaceuticals has a 52-week low of $4.20 and a 52-week high of $9.86.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.